CELGENE CORP found using ticker (CELG) have now 20 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 163 and 84 with a mean TP of 102.78. Given that the stocks previous close was at 87.47 this indicates there is a potential upside of 17.5%. The 50 day MA is 82.57 while the 200 day moving average is 81.69. The company has a market capitalisation of $61,558m. You can visit the company’s website by visiting: http://www.celgene.com
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company’s products also include IDHIFA, a small molecule inhibitor of the isocitrate dehydrogenase 2 to treat acute myeloid leukemia (AML); VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; and THALOMID to treat patients with MM and erythema nodosum leprosum. Its clinical stage products comprise OTEZLA to treat various immune-inflammatory diseases; luspatercept for the treatment of patients with beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; CC-92480 to treat multiple myeloma; and durvalumab, an anti-PD-L1 antibody for hematological cancers. The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Vividion Therapeutics, Inc.; Jounce Therapeutics, Inc.; Prothena Corporation plc; Zymeworks Inc.; and Evotec AG, as well as strategic collaborations with Skyhawk Therapeutics, Inc., Dragonfly Therapeutics, Inc., Obsidian Therapeutics, Philogen S.p.A., and Kyn Therapeutics. The company was founded in 1980 and is headquartered in Summit, New Jersey.